About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

​About Greater Manchester Health and Social Care Partnership

Greater Manchester Health and Social Care Partnership is the body made up of the 37 NHS organisations and local authorities in the city region, overseeing the £6bn devolved health and social care budget here. More information at www.gmhsc.org.uk

About Health Innovation Manchester

Health Innovation Manchester (HInM) is a partnership between the region's academic and research institutions, our social care and NHS providers, and industry. Our purpose is to align the strengths of this partnership to the health needs of GM's 2.7m citizens, and accelerate the discovery, development, and delivery of innovations which will keep citizens in good health and improve treatments and outcomes for those in ill-health.

HInM's added value as a partnership is to create a "one team" approach to tackling Greater Manchester health challenges, by:

Providing a single powerful brand for all GM partners' work on health innovation, which will attract the best industry partners from across the world

Working with partners to agree a clear and shared set of health improvement goals where innovation is both necessary and possible

Supporting the shift toward a more joined-up, person-centred approach to innovations across the entire population health, primary, secondary and social care systems

Providing straightforward, agile, system wide processes to support industry innovators with new products or services to get trials underway, and to ensure that successful trials are followed quickly by implementation across Greater Manchester

www.healthinnovationmanchester.com

Salford Lung Study - published in the New England Journal of Medicine

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice, Vestbo J et al, N Engl J Med 2016; 375:1253-1260 September 29, 2016 DOI: 10.1056/NEJMoa1608033

Notes for Editors

Salford Lung Study

Greater Manchester is already the global leader in real time clinical trials.  New relationships are developing, building on the success and learnings from the pioneering Salford Lung Study.

The research study involved 2,802 patients with chronic obstructive pulmonary disease (COPD) and 3,000 specially trained health care staff across 80 GP practices and 130 pharmacies in Salford and South Manchester. 

Sponsored by pharmaceutical company GSK and delivered in partnership with healthcare organisations in Greater Manchester, the ground-breaking study was the world's first Randomised Controlled Trial (RCT) that used a single electronic medical record linking primary care, secondary care and pharmacy data. The study included a broad and inclusive population of patients in an everyday clinical practice setting, embracing a novel approach to clinical trial design. 

The reason this could take place in this way was because of the Salford integrated electronic healthcare record. This enabled patients to be identified and followed through the process far more easily than in other trials. It also provided researchers with a breadth of clinical data about how patients use their medicines. It was designed to be as close to real life care for patients and clinicians, so that the only difference between the two groups was that one used the new inhaler and the control group received what they agreed with their clinician was most suitable for them.

The study showed that eight per cent fewer patients taking the new inhaler experienced moderate or severe problems caused by COPD, ranging from worsening of respiratory symptoms that led to treatment with medication, hospital admissions or clinic visits. 

Media enquiries


+44 (0) 20 7747 7147​​